$PDSB

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune

PDS Biotechnology (PDSB) disclosed that Nant Capital, led by Patrick Soon-Shiong, acquired a 19.9% stake in the company. Nant Capital purchased 13,005,334 shares and warrants for $0.2825 per share. The investment includes a milestone closing contingent on PDS0301's Phase 3 trial submission to the FDA, with Nant Capital obligated to invest $10M. Soon-Shiong and James Banaag joined PDS Biotechnology's board.

PDS Biotech (PDSB) announced a $22.55M PIPE financing for late-stage cancer drug development, shares up 50.64%. Avaí Bio (AVAI) completed cell bank testing, shares up 14.29%. Clene (CLNN) priced a $4M offering, shares up 25.25%. NurExone (NRX.V) partnered with NanoPass, shares up 8.06%. Cardiff Oncology (CRDF) settled a licensing dispute, shares up 4.58%. Indaptus (INDP) shares surged 16.88% without specific news.

PDS Biotechnology (PDSB) retired a $6M debt, paying $4.6M in principal and interest. It raised $11.3M via a PIPE financing led by Nant Capital. Funds will support working capital and clinical trials, including PDS0301's late-stage development. Nant committed additional funding and secured a licensing option for PDS0101. The company added two Nant-affiliated directors to its board.

PDS Biotechnology (PDSB) repaid a $6M promissory note to Yorkville early on Sep 14, 2026, covering $4.6M in principal and interest. The note, issued Jun 15, 2026, had a 10% annual interest rate and was due Jun 15, 2027. The early redemption reduced debt and interest expenses without penalties, according to the company.

PDS Biotechnology (PDSB) raised $11.3M in a PIPE deal led by Dr. Patrick Soon-Shiong, who joined the board. The funds will repay debt and advance clinical programs, including PDS0301 for colorectal cancer. Soon-Shiong's NantWorks gained a licensing option for PDS0101.

PDS Biotechnology Corp (PDSB) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Exhibit 99.1 PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks Pr

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

PDS Biotechnology (PDSB) shares surged 183% to $0.62 after announcing a $22.55 million PIPE financing led by Nant Capital, with participation from existing investors. Nant will gain board representation if it holds 15% or more of the company's stock.

U.S. stocks fell Tuesday, with the Dow Jones dropping 450 points. The NFIB Small Business Optimism Index declined to 98.7 in August. PDS Biotechnology (PDSB) shares surged 178% after raising $22.55 million in equity funding. Energy shares rose 1.4%, while healthcare stocks fell 2.2%.